Indonesia Cancer Pain Management Market Analysis Report [2022-30]

Indonesia Cancer Pain Management Market Analysis

$ 3999

The Indonesia Cancer Pain Management market is projected to grow from $39.12 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The main factors driving the growth would be rising cancer cases and government support and initiatives. The market is segmented by drug type and by disease. Some of the major players include Novell Pharmaceutical Laboratories, Hisamitsu Pharmaceutical, Pfizer, Sanofi, and Abbott.

ID: IN10IDHS002 CATEGORY: Healthcare Services GEOGRAPHY: Indonesia AUTHOR: Neha Davda

Buy Now

Indonesia Cancer Pain Management Market Executive Summary

The Indonesia Cancer Pain Management market is projected to grow from $39.12 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Indonesia's national healthcare spending as a share of GDP in 2019 was 2.9% or $120.12 per person. The overall amount spent on healthcare per person in Indonesia is quite low, just above that of Laos, Cambodia, and Myanmar, which have far lower national per capita incomes.

Most acute pain is produced by therapy or diagnostic procedures, but most chronic pain is caused by the illness. Radiotherapy and chemotherapy may cause unwanted problems that last long after the course of treatment is complete. The presence of pain is primarily influenced by cancer's location and stage. Malignant cancer patients suffer pain at all times, and two-thirds of those with advanced cancer do so to such an extent that it negatively impacts their sleep, emotions, social interactions, and everyday activities. With over 270 Mn people, Indonesia is a middle-income nation with a rising cancer burden.

indonesia cancer pain management market analysis

Market Dynamics

Market Growth Drivers

The cancer pain management market in Indonesia is expected to be driven by factors such as rising cancer cases and government support and initiatives. According to Globocan, the number of new cases of cancer increased to 141.1 per 100,000 people in the year 2020, but the number of cancer fatalities decreased to 85.1 per 100,000 people. To address the rising cancer burden in the country, the Republic of Indonesia's Minister of Health recently re-released a Ministerial Regulation that oversees and enforces a national prevention program for breast and cervical cancers, two illnesses that are incredibly common there. The program focuses on public health outreach to the general public or community organizations as well as preventative initiatives such as widespread screening, early identification, and referrals among primary healthcare facilities.

Market Restraints

The lack of adequate healthcare infrastructure, especially in rural areas, and the adverse side effects of using pain management drugs are expected to limit the growth of the pain management market in the country.

Competitive Landscape

Key Players

Novell Pharmaceutical Laboratories (IDN)
Hisamitsu Pharmaceutical
Pfizer
Sanofi
Abbott

Notable Recent Deals

December 2022: Sanofi and Innate Pharma announced the expansion of their collaboration, with Sanofi acquiring a license for an NK cell engager program from Innate's ANKETTM (Antibody-based NK Cell Engager Therapeutics) technology that targets B7H3. Sanofi will also have the option of adding up to two more ANKETTM targets. Sanofi will be in charge of all development, production, and commercialization following candidate selection.

Healthcare Policies and Regulatory Landscape

Indonesia has a number of laws and policies in place to deal with cancer pain, including the provision of necessary analgesics. The Ministry of Health is in charge of monitoring how these rules and policies are put into practice. The National Agency of Drug and Food Control (BPOM) oversees the use and dissemination of pharmaceuticals, especially painkillers, throughout the nation.

Reimbursement Scenario

Depending on the patient's health insurance coverage and financial situation, several cancer pain management reimbursement scenarios are applicable in Indonesia. Some cancer pain medications are covered by the Ministry of Health for people with government-funded health insurance (JKN). However, the coverage might not be comprehensive, thus some costs could still need to be covered by the patients themselves. Cancer pain management may or may not be covered for patients with private health insurance, depending on their particular insurance plan. While some private insurance plans might cover cancer pain management medications and treatments, others might have restrictions or exclusions.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.